Anaerobe targeted enzyme-mediated prodrug therapy

US6416754B1 · kind B1 · utility

Assignees

• The Board of Trustees of the Leland Stanford Junior University · US
• Microbiological Research Authority (MRA) acting through the Centre for Applied Microbiology and Research (CAMR) · GB

Inventors

• John Martin Brown · Redwood City, US
• Nigel P. Minton · Salisbury, GB
• Amato J. Giaccia · Stanford, US

Key dates

• Filing date: Jul 23, 1996
• Grant date: Jul 9, 2002
• Expiry date: Jul 23, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12R2001/145
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.